Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling

Immune-checkpoint therapy has failed to show significant benefit in glioblastoma (GBM) patients. Immunologic subtypes of GBM are necessary to identify patients who might benefit from immune-checkpoint therapy. This study reviewed 152 GBM samples from The Cancer Genome Atlas (TCGA) and 214 GBM sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Shengrong, Li, Mingdong, Liu, Jia, Yang, Yi, Li, Guangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202515/
https://www.ncbi.nlm.nih.gov/pubmed/32310827
http://dx.doi.org/10.18632/aging.103065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202515/
https://www.ncbi.nlm.nih.gov/pubmed/32310827
http://dx.doi.org/10.18632/aging.103065

Ejemplares similares